News | January 01, 2025
Anthem Biosciences files DRHP for Rs. 3,395 crore IPO
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
In 2020, CORXEL acquired the rights to develop and commercialize aficamten in Greater China
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)
Immedica to commence a cash tender offer to acquire all issued and outstanding shares of Marinus for an enterprise value of approximately US$ 151 million
Parents, teachers, and caregivers play a vital role in spotting early signs of schizophrenia
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
GEMTESA is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH
The company will receive an upfront payment of Euro 100 million (Rs. 880 crores) for product development and site approval from European authorities
The technical program will run in four sessions and a panel discussion on “Challenges in translation of medical technologies”
The transaction is expected to result in approximately $175 million to support further development of IMG-007
Subscribe To Our Newsletter & Stay Updated
